Company news
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news
Karyopharm Therapeutics Inc. news releases on 6ix. Latest, Mar 14, 2022: Karyopharm Names New Head of Investor Relations
Press releases — page 3
Karyopharm Names New Head of Investor Relations
March 13, 2022
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
February 28, 2022
Karyopharm Announces Changes to Its Clinical Leadership Team
February 21, 2022
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
February 7, 2022
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
February 7, 2022
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
January 23, 2022
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
January 9, 2022
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
January 9, 2022
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
December 20, 2021
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
December 10, 2021
Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors
December 5, 2021
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis
December 5, 2021
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
December 1, 2021
Karyopharm to Host Virtual Investor Day on December 8, 2021
November 30, 2021
Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition
November 3, 2021
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights
November 2, 2021
Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome
October 20, 2021
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
August 4, 2021
Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021
July 28, 2021
Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis
July 27, 2021
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
June 23, 2021
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
June 8, 2021
Karyopharm Announces Key Changes to Its Commercial Leadership Team
June 7, 2021
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
June 2, 2021
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
June 1, 2021
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
May 18, 2021
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 2, 2021
Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021
April 27, 2021
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
April 18, 2021
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
March 28, 2021
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
February 10, 2021
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
February 3, 2021
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
January 28, 2021
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
January 10, 2021
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
December 17, 2020
Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2020
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
December 10, 2020
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
December 6, 2020
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2020
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
November 11, 2020
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
November 3, 2020
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
November 1, 2020
Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020
October 25, 2020
Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19
October 5, 2020
Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020
September 13, 2020
Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors
August 30, 2020
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
August 3, 2020
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
July 27, 2020
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
July 19, 2020
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
July 16, 2020